SEC Form DEFA14A filed by X4 Pharmaceuticals Inc.

4/25/25 4:07:42 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

DEFA14A 1 a2025defa14a.htm DEFA14A Document

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐						Preliminary Proxy Statement
☐						Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐						Definitive Proxy Statement
☒						Definitive Additional Materials
☐						Soliciting Material Pursuant to § 240.14a-12

X4 Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of filing Fee (Check the appropriate box):

☒

No fee required.

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Date	Price Target	Rating	Analyst
12/12/2023	$3.00 → $1.00	Buy → Neutral	B. Riley Securities
8/30/2023	$3.00	Buy	B. Riley Securities
12/22/2022	$3.00	Overweight	Cantor Fitzgerald
12/12/2022	$3.00	Overweight	Piper Sandler
12/14/2021	$21.00 → $11.00	Buy	HC Wainwright & Co.

Recent Analyst Ratings for
$XFOR